Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Pharmaceuticals, Biotechnology and Life Sciences
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
Due to an increase in the incidence of medical ailments, the marketstudied is expected to grow over the forecast period.
Second Launch@Shares Competition Announced in Collaboration withMTTC/MALSI Conference and MassBio’s MassCONNECT Program
The global food enzymes market is expected to grow at a CAGR of 7.5%from 2019 to reach $3,125.1 million by 2024 from $2,176.9 million in2019.
Nuvera launches ThePURE Report, the first independent, standardized, annual assessmentof healthcare provider (HCP) satisfaction with pharmaceutical companies’patient support services, including their industry rankings againstcompetition.
Denali has reported net loss of $39.0 million in the first quarter 2019, compared with a net loss of $23.7 million same period last year.
GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting
59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).